Prominin 2 decreases cisplatin sensitivity in non-small cell lung cancer and is modulated by CTCC binding factor

Tang, Jiyang; Shu, Dejun; Fang, Zhimin; Yang, Gaolan

doi:10.2478/raon-2023-0033

Abstract

Background

Non-small cell lung cancer (NSCLC) is the major pathological type of lung cancer and accounts for the majority of lung cancer-related deaths worldwide. We investigated the molecular mechanism of prominin 2 (PROM2) involved in cisplatin resistance in NSCLC.

Patients and methods

The GEO database was analyzed to obtain differential genes to target PROM2. Immunohistochemistry and western blotting were used to detect protein expression levels. To examine the role of PROM2 in NSCLC, we overexpressed or knocked down PROM2 by transfection of plasmid or small interfering RNA. In functional experiments, CCK8 was used to detect cell viability. Cell migration and invasion and apoptosis were detected by transwell assay and flow cytometry, respectively. Mechanistically, the regulation of PROM2 by CTCF was detected by ChIP-PCR. In vivo experiments confirmed the role of PROM2 in NSCLC.

Results

GEO data analysis revealed that PROM2 was up-regulated in NSCLC, but its role in NSCLC remains unclear. Our clinical samples confirmed that the expression of PROM2 was markedly increased in NSCLC tissue. Functionally, Overexpression of PROM2 promotes cell proliferation, migration and invasion, and cisplatin resistance. CTCF up-regulates PROM2 expression by binding to its promoter region. In vivo experiments confirmed that PROM2 knockdown could inhibit tumor growth and increase the sensitivity of tumor cells to cisplatin.

Conclusions

PROM2 up-regulation in NSCLC can attenuate the sensitivity of NSCLC cells to cisplatin and promote the proliferation, migration and invasion of tumor cells. PROM2 may provide a new target for the treatment of NSCLC.

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29. doi: 10.3322/caac.21254
Open DOI Search in Google Scholar Back to article
Xu Y, Hu Y, Xu T, Yan K, Zhang T, Li Q, et al. RNF8-mediated regulation of Akt promotes lung cancer cell survival and resistance to DNA damage. Cell Rep 2021; 37: 109854. doi: 10.1016/j.celrep.2021.109854
Open DOI Search in Google Scholar Back to article
Kumar V, Yadavilli S, Kannan R. A review on RNAi therapy for NSCLC: opportunities and challenges. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021; 13: e1677. doi: 10.1002/wnan.1677
Open DOI Search in Google Scholar Back to article
Kryczka J, Kryczka J, Czarnecka-Chrebelska KH, Brzezianska-Lasota E. Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy. Int J Mol Sci 2021; 22: 8856. doi: 10.3390/ijms22168885
Open DOI Search in Google Scholar Back to article
Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 2021; 27: 1345–56. doi: 10.1038/s41591-021-01450-2
Open DOI Search in Google Scholar Back to article
Saha SK, Islam SMR, Kwak KS, Rahman MS, Cho SG. PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis. Cancer Gene Ther 2020; 27: 147–67. doi: 10.1038/s41417-019-0109-7
Open DOI Search in Google Scholar Back to article
Luo W, Wang J, Xu W, Ma C, Wan F, Huang Y, et al. LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer. Cell Death Dis 2021; 12: 1043. doi: 10.1038/s41419-021-04296-1
Open DOI Search in Google Scholar Back to article
Brown CW, Amante JJ, Chhoy P, Elaimy AL, Liu H, Zhu LJ, et al. Prominin2 drives ferroptosis resistance by stimulating iron export. Dev Cell 2019; 51: 575–86.e574. doi: 10.1016/j.devcel.2019.10.007
Open DOI Search in Google Scholar Back to article
Brown CW, Chhoy P, Mukhopadhyay D, Karner ER, Mercurio AM. Targeting prominin2 transcription to overcome ferroptosis resistance in cancer. EMBO Mol Med 2021; 13: e13792. doi: 10.15252/emmm.202013792
Open DOI Search in Google Scholar Back to article
Li W, Zhu Y, Zhang K, Yu X, Lin H, Wu W, et al. PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer. Exp Mol Med 2020; 52: 409–22. doi: 10.1038/s12276-020-0390-4
Open DOI Search in Google Scholar Back to article
Song SH, Kim TY. CTCF, cohesin, and chromatin in human cancer. Genomics Inform 2017; 15: 114–122. doi: 10.5808/GI.2017.15.4.114
Open DOI Search in Google Scholar Back to article
Guo Y, Perez AA, Hazelett DJ, Coetzee GA, Rhie SK, Farnham PJ. CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops. Genome Biol 2018; 19: 160. doi: 10.1186/s13059-018-1531-0
Open DOI Search in Google Scholar Back to article
Zhang B, Zhang Y, Zou X, Chan AW, Zhang R, Lee TK, et al. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma. J Pathol 2017; 243: 418–30. doi: 10.1002/path.4976
Open DOI Search in Google Scholar Back to article
Lai Q, Li Q, He C, Fang Y, Lin S, Cai J, et al. CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis. Aging 2020; 12: 16270–93. doi: 10.18632/aging.103648
Open DOI Search in Google Scholar Back to article
Sun Q, Zhang SY, Zhao JF, Han XG, Wang HB, Sun ML. HIF-1alpha or HOTTIP/CTCF promotes head and neck squamous cell carcinoma Progression and drug resistance by targeting HOXA9. Mol Ther Nucleic Acids 2020; 20: 164–75. doi: 10.1016/j.omtn.2019.12.045
Open DOI Search in Google Scholar Back to article
Li H, Lin PH, Gupta P, Li X, Zhao SL, Zhou X, et al. MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer. Mol Cancer 2021; 20: 118. doi: 10.1186/s12943-021-01418-3
Open DOI Search in Google Scholar Back to article
Wang S, Wang L, Hu H, Dong P. MiR-224 ameliorates inflammation and symptoms in mouse model of allergic rhinitis by targeting CDK9. Allergol Immunopathol 2021; 49: 80–8. doi: 10.15586/aei.v49i6.451
Open DOI Search in Google Scholar Back to article
He Y, Li Q, Zhou W, Gu Y, Jiang Y. Coniferyl aldehyde alleviates LPS-induced WI-38 cell apoptosis and inflammation injury via JAK2-STAT1 pathway in acute pneumonia. Allergol Immunopathol 2021; 49: 72–7. doi: 10.15586/aei.v49i5.464
Open DOI Search in Google Scholar Back to article
Yang Y, Yang X, Wu Y, Fu M. METTL3 promotes inflammation and cell apoptosis in a pediatric pneumonia model by regulating EZH2. Allergol Immunopathol 2021; 49: 49–56. doi: 10.15586/aei.v49i5.445
Open DOI Search in Google Scholar Back to article
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. doi: 10.3322/caac.21492
Open DOI Search in Google Scholar Back to article
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7–30. doi: 10.3322/caac.21387
Open DOI Search in Google Scholar Back to article
Nguyen TT, Gapihan G, Tetu P, Pamoukdjian F, El Bouchtaoui M, Leboeuf C, et al. Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes. Clin Transl Med 2020; 10: e198. doi: 10.1002/ctm2.198
Open DOI Search in Google Scholar Back to article
Liu W, Wang H, Bai F, Ding L, Huang Y, Lu C, et al. IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-kappaB. Cell Prolif 2020; 53: e12776. doi: 10.1111/cpr.12776
Open DOI Search in Google Scholar Back to article
Chaft JE, Shyr Y, Sepesi B, Forde PM. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer. J Clin Oncol 2022; 40: 546–555. doi: 10.1200/JCO.21.01589
Open DOI Search in Google Scholar Back to article
Taheri M, Shoorei H, Tondro Anamag F, Ghafouri-Fard S, Dinger ME. LncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin. Exp Mol Pathol 2021; 123: 104602. doi: 10.1016/j.yexmp.2021.104602
Open DOI Search in Google Scholar Back to article
Chen TY, Zhou J, Li PC, Tang CH, Xu K, Li T, et al. SOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signaling. Med Oncol 2022; 39: 36. doi: 10.1007/s12032-021-01626-3
Open DOI Search in Google Scholar Back to article
Wang W, Zhao M, Cui L, Ren Y, Zhang J, Chen J, et al. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer 2020; 19: 134. doi: 10.1186/s12943-020-01256-9
Open DOI Search in Google Scholar Back to article
Fang C, Wang Z, Han C, Safgren SL, Helmin KA, Adelman ER, et al. Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation. Genome Biol 2020; 21: 247. doi: 10.1186/s13059-020-02152-7
Open DOI Search in Google Scholar Back to article
Wang L, Peng Q, Yin N, Xie Y, Xu J, Chen A, et al. Chromatin accessibility regulates chemotherapy-induced dormancy and reactivation. Mol Ther Nucleic Acids 2021; 26: 269–279. doi: 10.1016/j.omtn.2021.07.019
Open DOI Search in Google Scholar Back to article
Han ML, Zhao YF, Tan CH, Xiong YJ, Wang WJ, Wu F, Fei Y, Wang L, Liang ZQ. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells. Acta Pharmacol Sin 2016; 37: 1606–1622. doi: 10.1038/aps.2016.93
Open DOI Search in Google Scholar Back to article